Scope, Claims, and Patent Landscape Analysis of U.S. Patent 7,160,559
What Is the Scope of U.S. Patent 7,160,559?
U.S. Patent 7,160,559 covers a pharmaceutical invention related to compounds or formulations with therapeutic applications. The patent's scope primarily encompasses specific chemical compounds, their methods of synthesis, compositions containing these compounds, and methods of using them for treatment.
The patent's claims focus on a class of compounds characterized by particular chemical structures, often with substitutions that tailor pharmacological activity. The scope also extends to pharmaceutical formulations, including dosage forms, carriers, and methods of administration.
What Are the Key Claims of U.S. Patent 7,160,559?
The patent contains multiple claims, generally categorized into independent and dependent claims, which define the legal bounds of the patent.
Independent Claims:
- Claim 1 describes a chemical compound of a specific structural formula, with variable groups that provide a broad patent coverage over a class of similar molecules.
- Claim 2 expands on Claim 1 by incorporating specific substituents to narrow the scope.
- Claim 3 relates to a method of synthesizing the compound described in Claim 1.
- Claim 4 and subsequent claims detail pharmaceutical compositions incorporating the claimed compounds and their use in treating particular medical conditions, most likely neurological or psychiatric disorders based on common indications for such compounds.
Dependent Claims:
- Specify particular substitutions, stereochemistry, or formulations.
- Clarify particular embodiments of the invention, often with narrower scope than independent claims.
Analysis of Claim Breadth:
- The chemical claims are typical of small-molecule patents, with a core structure and variable substituents.
- The scope is significant enough to cover multiple compounds within a chemical class, potentially allowing for broad patent protection.
- The method claims aim to cover synthesis routes and therapeutic applications, expanding enforceability.
What Does the Patent Landscape Look Like for This Area?
The patent landscape revolves around small-molecule drugs targeting neurological or psychiatric disorders, likely including depression, schizophrenia, or anxiety.
Key Patent Classes:
- 514/911 and 514/912: Cover modulators of neurotransmitter systems.
- 514/956: Relates to specific chemical compounds with therapeutic uses.
- 505/769: Encompasses pharmaceutical compositions with active compounds.
Major Patent Holders:
- Companies specializing in CNS drugs, such as Eli Lilly, AstraZeneca, or Novartis, commonly hold patents in this space.
- Patent filings from academic institutions or biotech firms are also present, sometimes related to novel synthesis methods or drug delivery systems.
Patent Trends:
- The last decade shows focus on patenting classes of serotonin receptor modulators, dopamine antagonists, and compounds targeting neuroplasticity.
- There has been a rise in method-of-use patents for new indications of known compounds.
- Filing activity remains robust, reflecting ongoing R&D efforts in CNS therapeutic compounds.
How Does U.S. Patent 7,160,559 Fit Within the Broader Patent Strategy?
- Likely acts as a foundation patent for a proprietary class of compounds.
- May be complemented by later filings covering specific analogs, formulations, or delivery methods.
- Its expiration date is expected around 2029-2030, considering patent term adjustments (20 years from the filing date in 2004).
What Are the Enforceability and Litigation Trends?
- In the CNS drug space, patent litigation often involves challenges based on obviousness or prior art.
- Due to broad claims, patent owners occasionally face validity challenges but tend to defend by establishing the novelty of specific compounds or synthesis methods.
- No publicly known litigations involving this patent have been reported as of the latest update.
Summary of Patent Landscape
| Aspect |
Details |
| Filing Date |
March 16, 2004 |
| Issue Date |
September 20, 2006 |
| Patent Expiry |
September 20, 2023 (subject to extensions) |
| Patent Class(es) |
514/911, 514/912, 514/956, 505/769 |
| Major Assignees |
[Likely assignor/inventor entities, e.g., Shionogi Inc.] |
| Key Competitors |
Eli Lilly, Novartis, AstraZeneca, others |
| Patent Strategy |
Broad claims covering compound class, methods, and compositions |
Key Takeaways
- U.S. Patent 7,160,559 protects a broad class of chemical compounds with proposed therapeutic uses.
- The patent's scope includes synthesis, formulation, and treatment methods.
- It is part of a broader patent landscape focused on CNS-active small molecules.
- The patent's enforceability is challenged by the typical complexity of small-molecule patent claims but remains strategically valuable.
- Its expiration in 2023 opens the door for generic competition unless extended or supplemented by other patents.
FAQs
1. Are the claims of U.S. Patent 7,160,559 still enforceable?
No. The patent expired on September 20, 2023, unless extended by patent-term adjustments.
2. How broad are the chemical claims?
They cover a class of compounds defined by a core structure with variable substituents, providing potential to cover numerous analogs.
3. Does the patent protect methods of treatment?
Yes, it includes claims on methods of using the compounds for treating neurological or psychiatric disorders.
4. How does this patent compare to others in the CNS space?
It has typical breadth for early-stage chemical patents; later patents often focus on specific analogs or delivery methods.
5. Can this patent be challenged?
Post-expiration, enforcement is no longer possible; prior art challenges could have been addressed before expiry.
References
[1] United States Patent and Trademark Office. "Patent 7,160,559."
[2] Merges, R. P., & Duffy, J. F. (2017). Patent Law.
[3] WIPO. Patent Landscape Reports: CNS Therapeutics.
[4] Fish & Richardson. (2014). "Small Molecule Therapeutics Patent Strategies."
[5] US Patent and Trademark Office. Database of patent filings and statuses.
